1例滤泡型淋巴瘤患者新型冠状病毒持续阳性的治疗及药学监护  

Treatment and pharmaceutical care of a case of follicular lymphoma with persistent positive SARS-Cov-2

作　　者：张捷青 叶晓芬 吕迁洲 李晓宇 陈淑靖[2] ZHANG Jie-qing;YE Xiao-fen;LYU Qian-zhou;LI Xiao-yu;CHEN Shu-jing(Department of Pharmacy,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Respiratory and Critical Care Medicine,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院药剂科,上海200032 [2]复旦大学附属中山医院呼吸与危重症医学科,上海200032

出　　处：《复旦学报（医学版）》2024年第4期632-637,642,共7页Fudan University Journal of Medical Sciences

基　　金：上海市临床重点专科建设项目(shslczdzk06504)。

摘　　要：新型冠状病毒(SARS-CoV-2,简称新冠病毒)感染可对部分患者构成重大威胁。罹患血液系统恶性肿瘤及接受抗肿瘤治疗的患者均可出现免疫抑制状态,其感染新冠病毒后出现严重并发症的风险增加,重症发生率和死亡率明显增加。本文详述了1例滤泡型淋巴瘤患者感染新冠病毒后的治疗过程。该患者在入院治疗期间反复进行核酸检测(RT-PCR),结果显示持续阳性近90天,经过5轮抗病毒治疗及糖皮质激素抗炎、低分子肝素抗凝、抗生素抗感染治疗,并辅以呼吸机支持治疗等,最终患者核酸转阴,顺利脱机出院。本研究总结了该病例的救治过程,以期为临床诊治提供参考和经验。SARS-CoV-2 has posed a significant threat to a subset of the patient population.The occurrence of hematological malignancies and tumor treatment can lead to immunosuppression in patients,which significantly increases the risk of serious complications,severe incidence and mortality after SARS-CoV-2 infection.The treatment of a patient with follicular lymphoma infected with SARS-CoV-2 was described in detail.The patient remained positive for RT-PCR tests during the hospitalization for nearly 90 days.After undergoing 5 rounds of antiviral treatment,along with glucocorticoid anti-inflammatory therapy,low-molecular-weight heparin for anticoagulation,antibiotics for infection control,and respiratory support through the use of a ventilator,the patient eventually obtained negative result of the RT-PCR test.Subsequently,the patient was successfully weaned from mechanical ventilation and discharged.By summarizing the treatment process of this case,we hoped to provide reference and experience for future clinical diagnosis and treatment.

关 键 词：重症肺炎 新型冠状病毒(SARS-CoV-2) 滤泡型淋巴瘤 药学监护 

分 类 号：R969[医药卫生—药理学]